Covidien has released its financial outlook for Mallinckrodt, the business that Covidien plans to spin off as a separate publicly traded company in mid-2013.
Mallinckrodt is projected to have total revenue growth of 7% to 11% compared to the previous year, with the company's Specialty Pharmaceuticals business growing 21% to 25% and its Global Medical Imaging business falling 3% to 7%.
Mallinckrodt's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) will be in the range of 17% to 21%. The company's fiscal year will end on September 27, 2013.
